Manesh R. Patel, MD, chair of AHA Scientific Sessions program, explains what he saw as the top takeaways from AHA 2022.

A photo essay from the American Heart Association (AHA) 2022 Scientific Sessions Nov. 5-7 in Chicago.

Watch our exclusive interview, recorded live at the AHA Scientific Sessions 2022 conference, with three investigators from the BEST-CLI trial. 

The American Heart Association 2022 Scientific Sessions included 35 late-breaking studies and 39 featured science sessions presented at the meeting in Chicago, Nov. 5-7. Here is the list of all these studies with links to more information on the data.

Former U.S. Surgeon General Jerome Adams spoke at the AHA 2022 Scientific Sessions and asked cardiologists to help end the COVID pandemic and tackle the even bigger epidemic of hypertension.

James Udelson, MD, an investigator involved with the PRECISE trial, explained how patient outcomes were improved by 70% from the current standard of care.

FDA Commissioner Robert Califf, MD, who is a cardiologist, spoke at the opening session of the American Heart Association about the need to step up and address two major problems in the American healthcare system. 

Jason Andrade, MD, director of electrophysiology, Vancouver General Hospital, and principal investigator of the PROGRESSIVE AF trial, explains how cryoablation can be used as a frontline treatment for atrial fibrillation (AFib) before drugs in this AHA late-breaker. 

Cian McCarthy, MD, Massachusetts General Hospital, and a member of the National Cardiovascular Data Registry (NCDR) Chest Pain-MI registry steering committee, explains a study of the NCDR data showing only 33% of hospitals are using high-sensitivity troponin.

The drug allows patients to take control over their condition with self administration and the therapy and may help lower healthcare costs and resource utilization by keeping these patients out of emergency rooms. 

Brian Lindman, MD, medical director of the Structural Heart and Valve Center, Vanderbilt University Medical Center, explains the new American Heart Association (AHA) Target Aortic Stenosis (AS) program to screen with echo to find more AS patients. 

However, researchers noted, there is still considerable room for improvement.

Telehealth can provide significant value when it comes to managing and monitoring patients with CVD or suspected CVD. A new scientific statement from the American Heart Association explores the latest details on this evolving treatment option. 

The SPYRAL HTN-ON MED renal denervation trial failed to show that renal denervation was superior to sham control at improving ambulatory blood pressure (ABPM), but that might have been due to patient lifestyle changes during COVID-19.

The more a patient has to pay for medications, the less likely they are to take them. This was the finding of a new study showing how copayments may be a barrier to drugs to treat pulmonary arterial hypertension.

“The evidence shows increasingly that it’s time to rethink how we approach the treatment of AFib,” one researcher said.

American College of Cardiology President Edward Fry, MD, spoke about recent Medicare cuts at the American Heart Association Scientific Sessions conference in Chicago. 

The new analysis was presented at the AHA Scientific Sessions 2022 conference and simultaneously published in the Journal of the American College of Cardiology.

"We expected to see a significant improvement in outcomes for patients with severe or rapidly progressing cardiogenic shock who underwent early ECMO treatment," one specialist said. 

The new study, presented at the AHA Scientific Sessions 2022 conference in Chicago, focused on data from more than 2,000 patients.